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Abstract 
Background: CYP2E1 polymorphisms have been reported to influence individual’s breast cancer susceptibility as a 
phase I enzyme, but the results of these previous studies remain controversial. We performed a comprehensive meta-
analysis to assess their association.
Methods: A comprehensive search of literature included in various databases (PubMed, Web of Science and Google 
scholar), published before August 2016, was performed. Odds ratios (ORs) with 95% confidence intervals (CIs) calcu-
lated in fixed or random-effects models were used to estimate the strength of the associations between three poly-
morphisms of CYP2E1 and breast cancer susceptibility. Subgroup analysis, sensitivity analysis and test for publication 
bias were also performed. A total of 11 separate comparisons involving 4311 cases and 4407 controls were included 
in the meta-analysis.
Results: Our result showed that there was no significant association between the two common polymorphisms 
CYP2E1 rs2031920 C>T, CYP2E1*5 Rsa I/Rst I (c1/c2) and BC risk. For CYP2E1*6 Dra I (D/C) polymorphism, a significantly 
increased BC risk in the overall population was found in genetic model D/C vs. D/D (OR = 1.29, 95% CI = 1.04–1.61, 
P = 0.023) and C/C + D/C vs. D/D (OR = 1.25, 95% CI = 1.04–1.51, P = 0.019), together with subjects who have at 
least one C allele (C vs. D: OR = 1.46, 95% CI = 1.20–1.79, P < 0.001). Similar results were also found in subgroup analy-
ses in Caucasians of these three comparison models.
Conclusions: The present meta-analysis suggests that CYP2E1*6 Dra I (D/C) variation significantly associated with 
the risk of BC. Individuals with D/C and C/C + D/C genotypes or carried at least one C allele of CYP2E1*6 Dra I (D/C) 
polymorphism had a significant higher susceptibility to develop BC.
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Background
Worldwide, breast cancer (BC) represents the leading 
cause of female gynecological cancer death. Its estimated 
deaths (189,000) were reported almost equal to the esti-
mated number of deaths from lung cancer (188,000 
deaths) [1], indicating that BC has become a global bur-
den. Known risks factors contribute to BC included 
reproductive events, hormonal level, and family histories 
[2], but they account for less than 47% cases [3]. Other 
etiology, though remains unknown, is believed causing 
by an integrated function of carcinogen exposure and 
polymorphisms in genes, especially genes involved in 
carcinogen metabolism [4].
Cytochrome P4502E1 (CYP2El), a member of 
Cytochrome P450 (CYP) super-family which involved in 
the metabolism of many endogenous and exogenous sub-
stance, is of pivotal importance in metabolizing ethanol 
and low-molecular-weight carcinogens such as N-nitros-
amines in cigarettes [5, 6]. Alcohol intake, a risk factor for 
cancer of various organs, has been proved associated with 
BC [7]. The relationship between tobacco smoke and BC 
development, also continuously, been emphasized that 
smoking could increased breast cancer risk, no matter 
passively or actively [8]. Furthermore, their association 
with BC according to carcinogen-metabolizing geno-
type was also investigated by more than 50 epidemiologic 
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studies. Results indicating that gene polymorphisms, 
including CYP450s, glutathione S-transferases, N-acetyl-
transferases, and sulfotransferases, interacting with car-
cinogen exposure, may modified one’s susceptibility 
to cancer [9]. Among the various CYPs, CYP2E1 is an 
important Phase I enzyme involved in the metabolism of 
alcohol and tobacco-generated N-nitrosamines, altering 
its activity has been suggested might link to the develop-
ment of BC [4].
CYP2E1 is located at chromosome 10. So far, more than 
100 single nucleotide polymorphisms (SNPs) have been 
found (http://www.ncbi.nlm.nih.gov/SNP). However, 
only several common mutations were extensively inves-
tigated as they might alter the activity of CYP2E1 [10, 
11]. Rs3813867 G>C and rs2031920 C>T were two key 
SNPs among them, with the former one associated with 
Pst I restriction enzyme site and the later one with Rsa I 
restriction enzyme site, their linkage disequilibrium also 
lead to the CYP2E1*5 haplotype and form three types 
of distinct genotypes: (1) c1/c1(Rsa I+ Pst I−), homozy-
gous of normal alleles; (2) c1/c2, heterozygous; (3) c2/
c2 (Rsa I− Pst I+), homozygous alleles after nucleotide 
exchanged [12]. Another polymorphism, recognized by 
Dra I restriction enzyme in intron 6 (rs6413432), form 
CYP2E1*6 polymorphism and also result in three geno-
types: C/C, C/D and D/D [13].
The relationship between above CYP2E1 polymor-
phisms and BC has been investigated by various studies, 
however, presenting conflict results. One studies con-
ducted on patients suffering from primary unilateral BC 
demonstrated the absence of any association between 
CYP2E1*5 polymorphisms with BC, no matter in pre-
menopausal or postmenopausal women [14]. However, 
Wu et al. [15], who carried out a studies on non smoker 
and non drinker women, reported that individuals with 
the c2/c2 genotype of CYP2E1*5 had a lower BC risk than 
that of c1/c1 (OR = 0.24, 95% CI = 0.08–0.74). While the 
most recently study by Chong et  al. [16]. indicated that 
the c1/c2 genotype or c2 allele carriers with CYP2E1*5 
variation have an approximately 1.8-fold higher risk of 
BC. Such controversy results may due to the relatively 
low mutation frequency of CYP2E1 and small epide-
miologic studies with low statistic power; we therefore 
systematically reviewed and performed a meta-analysis 
to quantitatively evaluate the role of CYP2E1 polymor-
phisms in BC development.
Methods
Search strategy
A comprehensive search of literature listed in various 
databases (PubMed, Web of Science and Google scholar), 
published before August 2016, was performed using the 
following key words ‘breast cancer’ or’ ‘breast carcinoma’, 
‘polymorphism’ or ‘variant’ and ‘mutation’, all combined 
with Medical Subject Heading (MeSH) term ‘CYP2E1’. 
The eligible studies were retrieved, and their reference 
lists were screen by hand to find every relevant paper. 
No any restriction such as time and language was made 
during the searches, as well as attempts to obtain unpub-
lished studies.
Selection criteria
In this study, we performed the meta-analysis according 
to the proposal of Meta-analysis of Observational Studies 
in Epidemiology group (MOOSE) [17]. The eligible studies 
were requested to meet the following inclusion criteria: 
(1) any type of comparative study; (2) evaluated the asso-
ciation between CYP2E1 gene polymorphisms and breast 
cancer risk; (3) in cases and controls, provided sufficient 
data to estimate the odds ratio (OR) with their 95% confi-
dence intervals (95% CIs). Studies were excluded if one of 
them existed: (1) insufficient data to extract; (2) without 
control population; and (3) some CYP2E1 polymorphisms 
that rarely reported. If overlapping data was found, either 
the study with lower quality or the earlier published one 
would be excluded in the following analysis.
Data extraction
Data extraction from each eligible study was conducted 
by two independent investigators, which included: (1) 
the first author’s name; (2) year of publication; (3) study 
region or country; (4) ethnicity; (5) cancer confirmation; 
(6) sample size (both cases and controls); (7) source of 
control (together with matching criteria); (8) polymor-
phisms of CYP2E1; (9) genotyping method; (10) genotype 
distribution in cases and controls and whether P value of 
the control population consistent with the Hardy–Wein-
berg equilibrium (HWE). In the event of different results, 
discussion was conducted to solve the discrepancies. 
When a study reported the results on different CYP2E1 
polymorphisms, we treated them as separate studies in 
our meta-analysis.
Quality assessment
To evaluate the quality of the included studies, a set of 
predefined criteria originally proposed by Thakkinstian 
et al. [18]. was used. The predefined criteria, which cover 
the credibility of controls, the representativeness of cases, 
specimens of cases when determining genotypes, Hardy–
Weinberg equilibrium in controls, and total sample size, 
was structured as a 16-item list with scores ranging from 
0 to 15 by Qin et  al. [19]. and has been quoted by sev-
eral meta-analyses [20, 21] (see Additional file  1: Table 
S1). As done previously, the studies with scores ≥10 were 
defined as high-quality studies, while the rest were low-
quality studies.
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Statistical analysis
The association of each CYP2E1  polymorphisms with 
breast cancer risk was estimated by calculating pooled 
ORs and 95% CIs under different comparison models, 
including additive models, recessive model, and dominant 
model. Firstly, the heterogeneity between studies would 
be assessed by the Q test and I2 statistics. According to the 
presence (PQ < 0.1 or I2 ≥ 50%) or absence (PQ ≥ 0.1 and 
I2 < 50%) of heterogeneity, different models would be used 
to calculate the pooled ORs, with the former situation 
using DerSimonian–Laird random-effects model while 
the later using Mantel–Haenszel fixed-effects model. 
If heterogeneity existed, Galbraith plot analyses would 
be carried out to investigate the sources of heterogene-
ity among studies. Then, subgroup analysis by ethnicity 
would be performed to address possible effects of these 
polymorphisms on different population. To assess the sta-
bility of the results, sensitivity analysis was performed by 
sequential omission of individual studies, especially stud-
ies whose genotype frequencies in the control populations 
were deviated from HWE, as they may generate bias. 
HWE in the control group population, if not reported in 
the original article, would be tested via a goodness-of-fit 
Chi square test. Finally, for each polymorphism, the Begg’s 
funnel plots and Egger’s linear regression test was used to 
test the publication bias (P < 0.05 indicated a significant 
publication bias). All analyses were performed with Stata 
software (Stata/SE version 12.0, Stata Corp, College Sta-
tion, TX) and all P values were two-sided.
Results
Study characteristics
There were 47 published articles relevant to the search 
terms. By browsing the title and abstract, 25 studies were 
excluded because of obvious irrelevance. After a care-
ful full-text review of the remaining 22 studies, a further 
13 articles were removed: 7 were reviews; 2 were not 
case–control studies; 2 focus on other SNPs of CYP2E1 
or other cancer; and the rest 2 did not report sufficient 
data. Additional eligible studies were not found through 
manual search of the reference lists. Consequently, 
night case–control studies focus on three CYP2E1 poly-
morphisms (rs2031920 C>T, CYP2E1*5 Rsa I/Pst I and 
CYP2E1*6 Dra I) and breast cancer risk were included 
in our meta-analysis [14, 15, 22–27]. Among them, the 
study by Zgheib et al. [25]. and Chong et al. [16]. explored 
the relationship of CYP2E1 mutation and breast cancer 
risk in both CYP2E1*5 and CYP2E1*6 polymorphisms, 
and were treated independently. As a result, a total of 11 
separate comparisons involving 4311 cases and 4407 con-
trols were finally included in the meta-analysis. A sche-
matic representation showing the process of inclusion/
exclusion of studies was illustrated in Fig. 1.
Of all the selected articles, three studies consist of 
1915 cases and 1793 controls evaluated the associa-
tion of CYP2E1 polymorphisms and breast cancer risk 
in rs2031920 C>T polymorphism (one in African, one 
in Asian and one in a mixed population) [14, 22, 23]; 
another four studies, with a total of 906 cases and 961 
controls, was about CYP2E1*5 Rsa I/Pst I polymorphism 
(three in Asian and one in Arab) [15, 24, 25]; the rest four 
studies, including 1490 cases and 1653 controls, focus on 
CYP2E1*6 Dra I polymorphism (two in Caucasian, one 
in Arab and one in Asian) [25–27]. Among them, cases 
were major confirmed pathologically (8 studies) with 
their genotype determined using PCR–RFLP assays (7 
studies), the rest were histologically confirmed or not 
mentioned with genotyping via standard PCR methods 
or TaqMan™ assays. The genotype distributions of the 
controls in two studies were found to deviate from HWE 
in rs2031920 C>T polymorphism while others were all 
reported or calculated consistence with HWE. All studies 
included met quality criteria ranging from 9 to 14, hence 
two studies were regarded as low-quality and night was 
high-quality. Basic characteristics of all eligible studies 
were listed in Table 1.
Meta‑analysis results
The meta-analysis suggested that the rs2031920 C>T 
polymorphism was not associated with BC risk in all 
genetic models in the overall populations: (1) T vs. C 
(OR  =  0.91, 95% CI  =  0.75–1.10, P  =  0.317); (2) T/T 
vs. C/C (OR = 0.87, 95% CI = 0.27–2.87, P = 0.821); (3) 
C/T vs. C/C (OR = 0.94, 95% CI = 0.76–1.16, P = 0.549); 
(4) T/T + C/T vs. C/C (OR = 0.92, 95% CI = 0.75–1.13, 
P  =  0.434); (5) T/T vs. C/T  +  C/C (OR  =  0.87, 95% 
CI = 0.26–2.89, P = 0.825) (Fig. 2a). Moreover, no sub-
group analysis was conducted in this mutation due to all 
Fig. 1 Schematic representation of study selection procedure
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studies included were carried out in different ethnicity. 
Considering the significant heterogeneity found in T/T 
vs. C/C and T/T vs. C/T +  C/C, random-effects model 
were used in these comparison model, while the rest 
using fix-effects model.
For the CYP2E1*5 Rsa I/Pst I (c1/c2) polymor-
phism, we still failed to identify any significant asso-
ciation with BC susceptibility: (1) c2 vs. c1 (OR =  0.97, 
95% CI  =  0.80–1.17, P  =  0.718); (2) c2/c2 vs. c1/c1 
(OR =  0.74, 95% CI =  0.42–1.30, P =  0.300); (3) c1/c2 
vs. c1/c1 (OR = 1.03, 95% CI = 0.81–1.29, P = 0.797); (4) 
c2/c2 + c1/c2 vs. c1/c1 (OR = 1.00, 95% CI = 0.80–1.24, 
P = 0.994); (5) c2/c2 vs. c1/c2 + c1/c1 (OR = 0.75, 95% 
CI  =  0.43–1.30, P  =  0.303) (Fig.  2b). Subgroup analy-
sis, focus on Asian population due to the limited num-
ber of included studies, also found null association in all 
comparison models. As no obvious heterogeneity was 
observed, fix-effects model was used to pool all compari-
son data of this polymorphism.
With regard to the CYP2E1*6 Dra I (D/C) variation, 
our result indicated a significant increased BC risk in 
genetic model D/C vs. D/D (OR = 1.29, 95% CI = 1.04–
1.61, P  =  0.023) and C/C  +  D/C vs. D/D (OR  =  1.25, 
95% CI =  1.04–1.51, P  =  0.019) (Fig.  2c), as well as in 
allele model C vs. D (OR  =  1.28, 95% CI  =  1.05–1.55, 
P =  0.014). When stratified by ethnicity, similar results 
were also found in Caucasians in these three comparison 
models. Details were present in Table 2. Because no sig-
nificant heterogeneity existed among all the comparison 
models, fix-effects model were used.
Heterogeneity analysis
As significant heterogeneity was found in the T/T vs. 
C/C and T/T vs. C/T  +  C/C comparison models of 
rs2031920 C>T polymorphism, Galbraith plot analy-
ses were carried out to detect the possible source of 
heterogeneity. However, as show in Fig.  3, outliner was 
observed in neither T/T vs. C/C model nor T/T vs. 
C/T +  C/C model, indicating that the studies included 
in both two comparison models were not contributors to 
the heterogeneity.
Sensitivity analysis
Considering that there were two studies whose genotypes 
inconsistent with HWE in rs2031920 C>T variation, sen-
sitivity analysis were performed to see if any single study 
would greatly influenced the estimates of overall risk, 
our result showed that the pooled ORs did not materially 
altered with or without these studies (data not shown). 
But we could not conduct sensitivity analysis for T/T vs. 
C/C model and T/T vs. C/T + C/C model due to a lim-
ited study number in these two models (only three stud-
ies were included and one of them did not provided data 
in T/T genotype).
Table 1 Basic characteristics of all eligible studies in the meta-analysis
BC breast cancer, HC histologically confirmed, PC pathologically confirmed, NM not mentioned, PCR polymerase chain reaction, PCR–RFLP polymerase chain reaction–
restriction fragment length polymorphism, HB hospital-based, PB population-based, PI polymorphism(s) investigated, HWE Hardy–Weinberg equilibrium, QS quality 
score









Tunisia African 304/244 HC PCR–RFLP H-B rs2031920 C>T Yes 13
Sangrajrang, 
2010
Thailand Asian 570/479 PC PCR H-B rs2031920 C>T No 9
McCarty, 2012 Thailand Mix 1041/1070 PC TaqMan™ P-B rs2031920 C>T No 9
Choi, 2003 Korea Asian 346/377 HC PCR H-B CYP2E1*5 Rsa I/
Rst I
Yes 11
Wu, 2006 Taiwan Asian 262/225 PC PCR–RFLP H-B CYP2E1*5 Rsa I/
Rst I
Yes 11
Zgheib, 2013 Lebanese Arab 227/99 PC PCR–RFLP H-B CYP2E1*5 Rsa I/
Rst I
Yes 10
Chong, 2016 Malaysian Asian 71/260 PC PCR–RFLP H-B CYP2E1*5 Rsa I/
Rst I
Yes 11
Shields, 1996 New York, 
Niagara and 
Erie
Caucasian 272/334 PC PCR–RFLP P-B CYP2E1*6 Dra I Yes 14
Anderson, 2012 Canada Caucasian 920/960 NM PCR P-B CYP2E1*6 Dra I Yes 12
Zgheib, 2013 Lebanese Arab 227/99 PC PCR–RFLP H-B CYP2E1*6 Dra I Yes 10
Chong, 2016 Malaysian Asian 71/260 PC PCR–RFLP H-B CYP2E1*6 Dra I Yes 11
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Publication bias
To assess possible publication bias, Begg’s funnel plots 
and Egger’s tests were performed simultaneously. The 
funnel plots were symmetrical in all genetic models of 
three CYP2E1 polymorphisms, indicating no significant 
publication bias existed in all the articles included. Egger’s 
test, with all the P value larger than 0.05, also revealed no 
evidence of publication bias in our meta-analysis (Fig. 4).
Discussion
Breast cancer, of which heredity explains approxi-
mately 10–15% of the cases, with only 5% can be clari-
fied by known genetic polymorphisms such as BRCA1 
and BRCA2 [28]. Such fact suggesting that other poten-
tial, common, but low-penetrance genetic variants may 
contribute to individual’s susceptibility to breast cancer. 
CYP2E1, a Phase I enzyme responsible for the metabolic 
activation of various carcinogens such as N-nitrosamine-
san and alcohol, was in different activity among indi-
viduals [12]. It has been assumed that polymorphisms 
of CYP2E1*5 and CYP2E1*6 may lead to a decreased 
activity in CYP2E1 enzyme, thus linked to a lower risk of 
cancer. Nevertheless, the power of a single study was too 
small to draw a precise conclusion, we therefore investi-
gated breast cancer and CYP2E1 polymorphisms in these 
common mutations using a meta-analysis.
However, in the present study, no significant associa-
tion was found between SNP rs2031920 C>T polymor-
phism and BC. The haplotype CYP2E1*5, which consist 
of SNP rs2031920 C>T and 3813867 G>C, also failed to 
identify any significant association with BC risk. Single 
SNP rs3813867 G>C was also taken into consideration, 
but further analysis was not carried out due to the sub-
optimal study numbers (n  =  1) [27]. Such insignificant 
Fig. 2 Forest plots of CYP2E1 gene polymorphisms and breast cancer (BC) risk. a Forest plots of CYP2E1 rs2031920 C>T polymorphism and BC risk 
(contrast T/T + C/T vs. C/C). b Forest plots of CYP2E1*5 Rsa I/Rst I (c1/c2) polymorphism and BC risk (contrast c2/c2 + c1/c2 vs. c1/c1). c Forest plots of 
CYP2E1*6 Dra I (D/C) polymorphism and BC risk (contrast C/C + D/C vs. D/D); all using a fix-effect model
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results may be partially attributed to the different dis-
tribution of the CYP2E1*5 polymorphism between var-
ies races, with the rarest 0.05 in Caucasians and the 
highest 0.23 in oriental populations [12]. Nevertheless, 
after stratified the study populations into different races, 
where we mainly focus on Asian populations, the results 
still failed to indicate any association between CYP2E1*5 
polymorphism and BC development. The pooled results 
of rs2031920 C>T SNP and BC risk were consistent with 
those studies included in the present meta-analysis, all 
indicating an insignificant relationship between them; 
and the overall results of CYP2E1*5 polymorphism and 
BC were also accordance with half of those included, 
though one of the rest observed a decreased risk of BC 
while another revealed an increased risk. Taken together, 
it may be concluded that CYP2E1*5 polymorphisms are 
not associated with BC risk in the overall population.
Interestingly, when considering the CYP2E1*6 poly-
morphism, our study found that individuals with the D/C 
and C/C + D/C genotype had a significantly higher risk 
of BC compared to those with the D/D genotype, simi-
lar increased result was also found in the C allele carri-
ers when compared with the D allele carriers, especially 
in Caucasian population. These results suggested that 
polymorphism in CYP2E1*6 could be a risk factor for 
BC development. But such result was inconsistent with 
those of the original studies, of which all suggested no 
significant relationship between any comparison model 
of CYP2E1*6 variation and BC development.
Actually, our results should explain with caution as 
there is increasing evidence that metabolizing enzymes 
do not act alone. In the study carried out by Choi et al. 
[24]. that explored the role of alcohol and genetic poly-
morphisms of CYP2E1*5 in BC development, no 
Table 2 Meta-analysis of the CYP2E1 gene polymorphisms on breast cancer risk
F fixed-effects model, R random-effects model
Italic values indicate significant difference (p < 0.05)
Comparison Population No. of studies Test of association Mode Heterogeneity
OR (95% CI) P value I2 (%) P value
rs2031920 C>T
 T vs. C Overall 3 0.91 (0.75–1.10) 0.317 F 0.0 0.380
 T/T vs. C/C Overall 3 0.87 (0.27–2.87) 0.821 R 64.0 0.096
 C/T vs. C/C Overall 3 0.94 (0.76–1.16) 0.549 F 0.0 0.414
 T/T + C/T vs. C/C Overall 3 0.92 (0.75–1.13) 0.434 F 0.0 0.447
 T/T vs. C/T + C/C Overall 3 0.87 (0.26–2.89) 0.825 R 64.3 0.094
CYP2E1*5 Rsa I/Pst I (c1/c2)
 c2 vs. c1 Overall 4 0.97 (0.80–1.17) 0.718 F 45.9 0.136
Asian 3 0.96 (0.80–1.16) 0.693 F 63.5 0.065
 c2/c2 vs. c1/c1 Overall 4 0.74 (0.42–1.30) 0.300 F 49.7 0.137
Asian 3 0.74 (0.82–1.30) 0.300 F 49.7 0.137
 c1/c2 vs. c1/c1 Overall 4 1.03 (0.81–1.29) 0.797 F 40.8 0.167
Asian 3 1.31 (0.74–2.34) 0.823 F 60.3 0.080
 c2/c2 + c1/c2 vs. c1/c1 Overall 4 1.00 (0.80–1.24) 0.994 F 44.4 0.145
Asian 3 1.00 (0.80–1.24) 0.965 F 62.6 0.069
 c2/c2 vs. c1/c2 + c1/c1 Overall 4 0.75 (0.43–1.30) 0.303 F 48.0 0.146
Asian 3 0.75 (0.43–1.30) 0.303 F 48.0 0.146
CYP2E1*6 Dra I (D/C)
 C vs. D Overall 4 1.28 (1.05–1.55) 0.014 F 0.0 0.532
Caucasian 2 1.32 (1.06–1.64) 0.014 F – –
 C/C vs. D/D Overall 4 1.47 (0.75–2.91) 0.266 F 0.0 0.667
Caucasian 2 1.66 (0.68–4.09) 0.268 F – –
 D/C vs. D/D Overall 4 1.29 (1.04–1.61) 0.023 F 0.0 0.667
Caucasian 2 1.32 (1.04–1.68) 0.025 F – –
 C/C + D/C vs. D/D Overall 4 1.25 (1.04–1.51) 0.019 F 0.0 0.724
Caucasian 2 1.26 (1.02–1.55) 0.032 F 18.0 0.269
 C/C vs. D/D + D/C Overall 4 1.39 (0.71–2.72) 0.339 F 0.0 0.654
Caucasian 2 1.58 (0.64–3.89) 0.318 F – –
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significant overall differences were found in the c1/c2 
genotype frequencies between BC cases and controls. 
However, after taking the drinking situation into con-
sideration, a 1.9-fold increasing risk for developing BC 
was found when comparing the ‘ever’-drinking women 
with the c2 mutation to the non-drinkers with the c1/
c1 mutation. Another study, investigated lifetime pas-
sive cigarette smoke exposures together with genetic 
Fig. 3 Galbraith plots of CYP2E1 gene polymorphisms and breast cancer (BC) risk in comparison models with significantly heterogeneity. a T/T vs. 
C/C in rs2031920 C>T polymorphism. b T/T vs. C/T + C/C in rs2031920 C>T polymorphism
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variants and BC risk in women who had never smoked, 
found that interaction between passive smoke exposure 
and CYP2E1*6 AA/AT (namely CC/CD) polymorphism 
could significant increased breast cancer risk among pre-
menopausal women [27]. In sum, such gene-environment 
interaction should be taken into consideration when 
investigating CYP2E1 polymorphism in the development 
of BC, however, due to the limited studies included, our 
study could not conduct further analysis with these fac-
tors taken into consideration.
To our knowledge, this is the first meta-analysis carried 
out to date to evaluate the role of CYP2E1 polymorphisms 
in breast cancer susceptibility. Despite the findings men-
tioned above, this study had several limitations. First, we 
haven’t taken the gene-environment interaction into con-
sideration. As is known to all, apart from genetic factors, 
smoking status and alcohol consumption are important risk 
factors for BC; however, we could not conduct subgroup 
analyses stratified by environmental exposure due to the 
limited information on our included studies. Second, the 
overall results of our study were based on crude ORs, but 
a more precise evaluation should be adjusted for the know 
risk factors such as age and menopause status. Third, the 
number of studies included in this study is relatively small, 
with three or four studies for each polymorphism, which 
may lead to low statistical power and prevent us from 
exploring a real association of the CYP2E1 polymorphism 
and BC risk. Fourth, because no attempts were made to 
access unpublished studies and studies in languages other 
than English, publication bias may exist, though results of 
our Begg’s funnel plot and Egger’s test did not reveal any 
publication bias. Fifth, as most studies were conducted in 
Asian and Caucasian population, the relative lack of ethnic 
diversity demands for further studies.
Fig. 4 Begg’s funnel plot analysis and Egger’s test to detect publication bias. Each point represents a separate study for the indicated association. a 
Begg’s funnel plot analysis and Egger’s test for contrast T/T + C/T vs. C/C. b Begg’s funnel plot analysis and Egger’s test for contrast c2/c2 + c1/c2 vs. 
c1/c1. c Begg’s funnel plot analysis and Egger’s test for contrast C/C + D/C vs. D/D
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Conclusions
Aside from the above limitations, this meta-analysis sug-
gests that CYP2E1*6 Dra I (D/C) polymorphism might be 
associated with increased BC risk, individuals with D/C 
and C/C + D/C genotypes or carried at least one C allele 
of CYP2E1*6 Dra I (D/C) polymorphism had a signifi-
cant higher susceptibility to develop BC, in Caucasians, 
particularly. Whereas, no any significant relationship 
between CYP2E1*5 Rsa I/Rst I (c1/c2), rs2031920 C>T 
polymorphisms and BC risk was found.
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